{"product_id":"novartis-business-model-canvas","title":"Novartis Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis: Business Model Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic core of Novartis with our comprehensive Business Model Canvas. This detailed breakdown reveals how they connect with key customer segments, deliver innovative value propositions, and build robust revenue streams in the competitive pharmaceutical industry. Discover the essential partnerships and cost structures that fuel their global success.\u003c\/p\u003e\n\u003cp\u003eReady to dissect a healthcare giant's strategy? Our full Novartis Business Model Canvas provides an in-depth look at their operational blueprint, from key resources to customer relationships. This actionable document is your key to understanding how they drive innovation and market leadership.\u003c\/p\u003e\n\u003cp\u003eGain a competitive edge by studying Novartis’s proven business model. Our complete canvas lays out their value creation process, revenue streams, and cost drivers in a clear, organized format. Download it now to benchmark your own strategy and identify growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Academia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis actively partners with prestigious universities and research institutions worldwide, fostering collaboration to push the boundaries of scientific discovery. These alliances are vital for identifying novel drug targets and propelling early-stage research, particularly in rapidly evolving fields such as gene therapy and xRNA technology.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Novartis continued to solidify these academic ties, exemplified by ongoing research collaborations with institutions like Harvard University and the University of Zurich. Such partnerships grant Novartis access to groundbreaking research, innovative technologies, and specialized scientific talent, accelerating the development of next-generation medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech and Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis actively cultivates strategic alliances and licensing agreements with other biotech and pharmaceutical firms. These collaborations are crucial for broadening its drug pipeline and enhancing its technological expertise. For instance, in 2024, Novartis continued to leverage these partnerships to gain access to novel therapeutic candidates and advanced platforms, often focusing on areas that align with its core therapeutic franchises.\u003c\/p\u003e\n\u003cp\u003eThese alliances frequently take the form of co-development or co-commercialization deals. Such arrangements enable Novartis to share risks and rewards while tapping into external innovation. In 2024, the company’s strategic focus on bolt-on acquisitions also underscored its commitment to rapidly integrating promising technologies and assets from smaller biotech players, further accelerating its growth and competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis heavily relies on Contract Research Organizations (CROs) to execute its extensive clinical trial programs. These partnerships are crucial for managing the complexities of drug development, from patient recruitment and data collection to regulatory submissions. For instance, in 2024, Novartis continued to leverage CROs for a significant portion of its global Phase III trials, a common practice in the industry to ensure efficient and compliant study execution.\u003c\/p\u003e\n\u003cp\u003eBy outsourcing these specialized functions, Novartis gains access to a vast network of expertise and resources, enabling them to scale research efforts rapidly and tap into diverse patient populations worldwide. This strategic outsourcing is vital for accelerating the development timeline and navigating the rigorous demands of regulatory agencies like the FDA and EMA, ultimately bringing innovative therapies to patients faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovartis actively collaborates with healthcare providers and hospitals to identify critical unmet medical needs and gather real-world evidence on treatment efficacy. This partnership is crucial for understanding patient journeys and ensuring our therapies reach those who can benefit most.\u003c\/p\u003e\n\u003cp\u003eEngaging physicians is key for product education and collecting vital feedback on treatment outcomes, directly informing our research and development efforts. In 2024, Novartis continued to invest in medical education programs, reaching thousands of healthcare professionals globally.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships with over 1,000 hospitals worldwide\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEngagement with 50,000+ healthcare professionals annually for educational initiatives\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReal-world evidence studies in oncology and cardiovascular disease showing significant patient outcome improvements\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernments and Non-Governmental Organizations (NGOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovartis actively partners with governments and NGOs to enhance medicine accessibility, especially in lower and middle-income nations, and to tackle critical public health issues.  These collaborations frequently center on making treatments more affordable, improving disease management strategies, and bolstering overall healthcare infrastructure.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, Novartis continued its commitment to expanding access to its cardiovascular medicines, with specific programs targeting hypertension and heart failure in regions like Sub-Saharan Africa.  These initiatives often involve tiered pricing models and patient assistance programs, demonstrating a tangible effort to bridge the affordability gap.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGovernmental Collaborations:\u003c\/strong\u003e Novartis works with health ministries to align drug development and distribution with national health priorities, ensuring that essential medicines reach populations effectively.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNGO Partnerships:\u003c\/strong\u003e Collaborations with NGOs focus on disease awareness campaigns, patient education, and strengthening local healthcare delivery systems, often targeting endemic diseases.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess Initiatives:\u003c\/strong\u003e By 2024, Novartis reported reaching millions of patients through its access programs, leveraging partnerships to overcome logistical and financial barriers to healthcare.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePublic Health Focus:\u003c\/strong\u003e Key areas of focus include non-communicable diseases and infectious diseases, where joint efforts aim to improve screening, diagnosis, and treatment adherence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis's Strategic Alliances: Powering Innovation and Global Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis’s key partnerships extend to Contract Manufacturing Organizations (CMOs) for specialized production needs, ensuring high-quality manufacturing of complex biologics and advanced therapies. These alliances are critical for scaling production efficiently and meeting global demand.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Novartis continued to strategically partner with CMOs to bolster its manufacturing capacity, particularly for its innovative cell and gene therapy platforms. For example, the company maintained agreements with leading CMOs to ensure the consistent supply of its CAR-T therapies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eType of Partner\u003c\/td\u003e\n\u003ctd\u003ePurpose of Partnership\u003c\/td\u003e\n\u003ctd\u003eKey Activities\/Focus Areas (2024)\u003c\/td\u003e\n\u003ctd\u003eImpact\/Benefit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic Institutions\u003c\/td\u003e\n\u003ctd\u003eEarly-stage research, novel drug targets\u003c\/td\u003e\n\u003ctd\u003eGene therapy, xRNA technology collaborations (e.g., Harvard, U Zurich)\u003c\/td\u003e\n\u003ctd\u003eAccess to cutting-edge science, talent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech\/Pharma Firms\u003c\/td\u003e\n\u003ctd\u003ePipeline expansion, technology access\u003c\/td\u003e\n\u003ctd\u003eCo-development, licensing, bolt-on acquisitions\u003c\/td\u003e\n\u003ctd\u003eBroadened therapeutic candidates, enhanced platforms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Research Organizations (CROs)\u003c\/td\u003e\n\u003ctd\u003eClinical trial execution\u003c\/td\u003e\n\u003ctd\u003eGlobal Phase III trial management, data collection\u003c\/td\u003e\n\u003ctd\u003eAccelerated development, regulatory compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\/Hospitals\u003c\/td\u003e\n\u003ctd\u003eUnmet needs identification, real-world evidence\u003c\/td\u003e\n\u003ctd\u003ePhysician engagement, patient outcome studies\u003c\/td\u003e\n\u003ctd\u003eInformed R\u0026amp;D, improved patient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments\/NGOs\u003c\/td\u003e\n\u003ctd\u003eMedicine accessibility, public health\u003c\/td\u003e\n\u003ctd\u003eAccess programs (Sub-Saharan Africa), disease awareness\u003c\/td\u003e\n\u003ctd\u003eImproved health outcomes, affordability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Manufacturing Organizations (CMOs)\u003c\/td\u003e\n\u003ctd\u003eSpecialized production, scaling\u003c\/td\u003e\n\u003ctd\u003eBiologics, cell \u0026amp; gene therapy manufacturing\u003c\/td\u003e\n\u003ctd\u003eHigh-quality supply, meeting global demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written business model tailored to Novartis' strategy of innovative medicines, detailing customer segments, channels, and value propositions.\u003c\/p\u003e\n\u003cp\u003eReflects Novartis' real-world operations and plans, organized into 9 classic BMC blocks with full narrative and insights for informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eNovartis's Business Model Canvas acts as a pain point reliever by providing a structured, visual framework to identify and address inefficiencies in their complex pharmaceutical operations.\u003c\/p\u003e\n\u003cp\u003eIt streamlines the process of understanding value propositions, customer segments, and key resources, thereby alleviating the pain of strategic ambiguity and siloed thinking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis's central pillar is its robust research and development (R\u0026amp;D) engine, dedicated to pioneering novel therapies. This commitment spans critical areas like oncology, cardiovascular health, immunology, and neuroscience. The process is rigorous, encompassing initial drug discovery, extensive preclinical evaluations, and multi-stage clinical trials to rigorously prove both safety and effectiveness.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Novartis invested approximately $10.4 billion in R\u0026amp;D, a testament to its focus on innovation. This significant expenditure fuels its pipeline, aiming to bring breakthrough treatments to patients. The company's strategy heavily relies on translating scientific advancements into tangible medical solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis’s key activities revolve around the intricate processes of manufacturing active pharmaceutical ingredients (APIs), biologics, and finished drug products. This encompasses a broad spectrum of production, from small molecule drugs to advanced biologics, all of which require specialized facilities and expertise.\u003c\/p\u003e\n\u003cp\u003eManaging a complex global supply chain is paramount to ensuring the consistent availability of medicines to patients worldwide. This involves intricate logistics, inventory management, and adherence to stringent regulatory standards across numerous countries.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Novartis continued its strategic investments to bolster its manufacturing capabilities and supply chain resilience. For instance, the company is significantly expanding its footprint in advanced therapies, including radioligand therapy (RLT) and siRNA, reflecting a commitment to innovation and future growth in these high-demand areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis's marketing and sales efforts are centered on promoting and selling its approved medicines to healthcare professionals, hospitals, and pharmacies globally. This involves crafting sophisticated commercial strategies and educating prescribers about the unique benefits of their therapies.\u003c\/p\u003e\n\u003cp\u003eThe company actively manages dedicated sales forces in critical markets, including the United States, China, Germany, and Japan, to ensure effective outreach and product adoption. In 2023, Novartis reported net sales of $45.4 billion, demonstrating the significant reach of its commercial operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovartis actively navigates intricate global regulatory landscapes to secure and maintain crucial drug approvals. This ongoing effort is paramount for market access and product lifecycle management. In 2024, the company continued to invest heavily in regulatory affairs, with a significant portion of its research and development budget allocated to preparing and submitting comprehensive dossiers to agencies like the FDA and EMA.\u003c\/p\u003e\n\u003cp\u003eEnsuring strict adherence to all pharmaceutical regulations and ethical standards is a core activity. This includes rigorous quality control, post-market surveillance, and compliance with evolving guidelines. Novartis' commitment to compliance underpins its reputation and the trust placed in its products by patients and healthcare professionals worldwide.\u003c\/p\u003e\n\u003cp\u003eKey activities in regulatory affairs and compliance include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDossier Preparation and Submission:\u003c\/strong\u003e Compiling and submitting extensive data packages for new drug applications (NDAs) and variations to existing marketing authorizations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-Market Surveillance:\u003c\/strong\u003e Monitoring drug safety and efficacy after approval, reporting adverse events, and managing product recalls if necessary.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdherence to GMP and GCP:\u003c\/strong\u003e Ensuring all manufacturing processes (Good Manufacturing Practices) and clinical trials (Good Clinical Practices) meet stringent regulatory requirements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Regulatory Strategy:\u003c\/strong\u003e Developing and executing strategies for obtaining and maintaining approvals in diverse international markets, considering varying regulatory pathways and requirements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovartis heavily relies on intellectual property management to safeguard its groundbreaking medicines. This involves securing and defending patents, which are crucial for maintaining market exclusivity and recovering the substantial costs associated with research and development. For instance, in 2023, Novartis continued to actively defend its patent portfolio, which underpins its innovative product lines.\u003c\/p\u003e\n\u003cp\u003eThe company’s strategy includes vigilant monitoring of the market for potential patent infringements and taking swift legal action when necessary. This proactive approach is vital to prevent unauthorized generic competition that could erode revenue streams from key therapies. Novartis's commitment to intellectual property protection is a cornerstone of its business model, enabling continued investment in future medical advancements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Protection:\u003c\/strong\u003e Novartis actively manages a vast patent portfolio covering its novel drug candidates and existing blockbuster products, ensuring market exclusivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment Recovery:\u003c\/strong\u003e Patents are critical for recouping the billions invested in the lengthy and complex process of drug discovery and development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDefense Against Generics:\u003c\/strong\u003e The company vigorously defends its patent rights against challenges from generic manufacturers to preserve its market share and pricing power.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic IP Portfolio:\u003c\/strong\u003e Novartis continuously assesses and updates its intellectual property strategy to align with its pipeline and evolving market dynamics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrafting Cures: Pharma's Journey from Discovery to Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovartis's key activities are deeply rooted in its extensive research and development to create new medicines, coupled with the precise manufacturing of these therapies. This is supported by a robust global supply chain ensuring product availability and aggressive marketing and sales to reach patients. Navigating complex regulatory environments and diligently protecting its intellectual property are also critical functions that underpin its operations and future innovation.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Novartis Business Model Canvas preview you are viewing is the exact document you will receive upon purchase. This means all sections, formatting, and content are identical to the final deliverable, ensuring no surprises. You'll gain full access to this comprehensive analysis, ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611284849017,"sku":"novartis-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/novartis-business-model-canvas.png?v=1754754527","url":"https:\/\/growthsharematrix.com\/products\/novartis-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}